Stockscreener 앱 받기
78.68
4.98%
3.73
시간 외 거래:
78.00
-0.68
-0.86%
전일 마감가:
$74.95
열려 있는:
$75.07
하루 거래량:
1.55M
Relative Volume:
0.75
시가총액:
$11.08B
수익:
$622.01M
순이익/손실:
$-271.86M
주가수익비율:
-36.62
EPS:
-2.1484
순현금흐름:
$-45.87M
1주 성능:
+7.52%
1개월 성능:
+6.45%
6개월 성능:
+36.34%
1년 성능:
+420.03%
1일 변동 폭
$74.07
$78.69
1주일 범위
$73.75
$78.69
52주 변동 폭
$14.30
$82.26
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
78.68 | 10.56B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus - Yahoo Finance
Arrowhead Pharmaceuticals (ARWR) Reports Clinical Findings for P - GuruFocus
Arrowhead presents plozasiran data on renal, hepatic impairment By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress - Arrowhead Pharmaceuticals, Inc.
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026 - Insider Monkey
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
ARROWHEAD PHARMACEUTICALS IN (ARWR) Technical Analysis - ChartMill
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next - TipRanks
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum - Barchart
Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Director Daniel Apel to offer 100,000 ARWR common shares (NASDAQ: ARWR) - Stock Titan
Insider Hongbo Lu notifies sale of 2,970 ARWR shares (NASDAQ: ARWR) - Stock Titan
James Hamilton to sell 10,000 shares (ARWR) after prior 10,000-share sale - Stock Titan
Arrowhead Pharmaceuticals eyes $4B Redemplo opportunity as RNAi pipeline readouts near - MSN
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options - Sahm
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
What is Zacks Research's Estimate for ARWR FY2026 Earnings? - MarketBeat
Baader Bank Aktiengesellschaft Purchases Shares of 14,194 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Insider Sell: Hongbo Lu Sells Shares of Arrowhead Pharmaceuticals Inc (ARWR) - GuruFocus
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 through May-14-2026 - marketscreener.com
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock - MarketBeat
Arrowhead director Lu Hongbo sells $228,333 of common stock - Investing.com
Arrowhead (NASDAQ: ARWR) director sells 2,970 shares under Rule 10b5-1 plan - Stock Titan
Arrowhead Pharmaceuticals, Inc.Common Stock (NQ: ARWR - FinancialContent
What is HC Wainwright's Forecast for ARWR Q3 Earnings? - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5 By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near - MarketBeat
ARWR Maintained by Bernstein -- Price Target Raised to $46.00 - GuruFocus
Sanford C. Bernstein Boosts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $46.00 - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5 - Investing.com
HC Wainwright Issues Optimistic Outlook for ARWR Earnings - MarketBeat
ARWR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum - Yahoo Finance
[144] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Arrowhead Pharmaceuticals: A True Inflection Point Has Arrived (NASDAQ:ARWR) - Seeking Alpha
Goldman Sachs Maintains Arrowhead Pharmaceuticals (ARWR) Neutral Recommendation - MSN
Arrowhead Pharmaceuticals Jumps 7.9% After RBC Capital Maintains Outperform - AlphaStreet
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year High on Analyst Upgrade - MarketBeat
Discipline and Rules-Based Execution in ARWR Response - Stock Traders Daily
Has Arrowhead Pharmaceuticals (ARWR) Run Too Far After Its 488% One Year Surge - Sahm
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Supports Bullish Narrative Despite High 54x P/E - Sahm
ViaSat, Arrowhead Pharmaceuticals, and SiTime Lead Stocks with High Returns - Markets Mojo
Arrowhead anticipates SHASTA-3/4 topline in Q3 while planning an SHTG sNDA before end of 2026 - MSN
Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets - TipRanks
ARWR Maintained by RBC Capital -- Price Target Raised to $87.00 - GuruFocus
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - MSN
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $110 - Moomoo
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $87 - Moomoo
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating - marketscreener.com
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $90 - Moomoo
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results - BioSpace
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):